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Abstract
Introduction: Emerging antimalarial drug resistance in mobile populations remains a significant public health concern. We
compared two regimens of dihydroartemisinin-piperaquine in military and civilians on the Thai-Cambodian border to
evaluate national treatment policy.
Methods: Efficacy and safety of two and three-day regimens of dihydroartemisinin-piperaquine were compared as a nested
open-label evaluation within a malaria cohort study in 222 otherwise healthy volunteers (18% malaria-infected at baseline).
The first 80 volunteers with slide-confirmed Plasmodium falciparum or vivax malaria were randomized 1:1 to receive either
regimen (total dose 360mg dihydroartemisinin and 2880mg piperaquine) and followed weekly for up to 6 months. The
primary endpoint was malaria recurrence by day 42. Volunteers with vivax infection received primaquine at study discharge
with six months follow-up.
Results: Eighty patients (60 vivax, 15 falciparum, and 5 mixed) were randomized to dihydroartemisinin-piperaquine.
Intention-to-treat all-species efficacy at Day 42 was 85% for the two-day regimen (95% CI 69–94) and 90% for the three-day
regimen (95% CI 75–97). PCR-adjusted falciparum efficacy was 75% in both groups with nearly half (45%) still parasitemic at
Day 3. Plasma piperaquine levels were comparable to prior published reports, but on the day of recrudescence were below
measurable in vitro piperaquine IC50 levels in all falciparum treatment failures.
Conclusions: In the brief period since introduction of dihydroartemisinin-piperaquine, there is early evidence suggesting
declining efficacy relative to previous reports. Parasite IC50 levels in excess of plasma piperaquine levels seen only in
treatment failures raises concern for clinically significant piperaquine resistance in Cambodia. These findings warrant
improved monitoring of clinical outcomes and follow-up, given few available alternative drugs.
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Introduction
Recent public health efforts have made considerable progress in
reducing the morbidity and mortality of malaria in Southeast Asia.
These advances are threatened by the emergence of documented
artemisinin resistance in four countries including Cambodia,
Myanmar, Thailand, and Vietnam [1]. Most notably, multi-drug
resistant Plasmodium falciparum along the western Cambodian-Thai
border is now resistant to both components of multiple artemisinin
combination treatments (ACTs), emphasizing the importance of
ongoing monitoring of antimalarial therapeutic efficacy and
resistance in this region [1–4].
Dihydroartemisinin-piperaquine is a fast-acting, potent artemi-
sinin derivative paired with a long-acting 4-aminoquinoline [5].
Several studies have demonstrated that dihydroartemisinin-piper-
aquine is safe and highly efficacious against multi-drug resistant
falciparum although recent reports suggest declining efficacy in
western Cambodia [2,6–9]. National distribution as the first-line
ACT for all malarial infection began in 2012, with introduction in
2006 in military personnel and in 2008 for Zone 1, a containment
area of antimalarial resistance along the western Cambodian-Thai
border [1,2,10].
At the time of this study, Cambodian national treatment
guidelines recommended artesunate plus mefloquine combination
therapy for falciparum infection and chloroquine monotherapy for
vivax infection. However, military practice guidelines employed
various two and three-day regimens of dihydroartemisinin-
piperaquine under the brand names Artekin, Artequick, and
Duocotexin, in order to improve compliance in austere settings. In
anticipation of the Cambodian national malaria control (CNM)
program’s plan to replace artesunate plus mefloquine with
dihydroartemisinin-piperaquine for all species, we conducted a
treatment study nested within a malaria cohort study in order to
provide evidence-based treatment policy recommendations. The
primary objective aimed to compare the efficacy of two and three-
day regimens of dihydroartemisinin-piperaquine in a dynamic
setting of emerging multi-drug resistance.
Materials and Methods
Ethics Statement
The study protocol was approved by specific institutional review
boards at participating institution including Walter Reed Army
Institute of Research (IRB#00000794), National Ethics Commit-
tee for Health Research in Cambodia (IRB#00003143), and
University of North Carolina (IRB#00002074). This trial was
registered prior to initiation (ClinicalTrials.gov identifier
NCT01280162) and adhered to CONSORT guidelines. All
participants provided written informed consent for participation,
collection of samples, and subsequent analyses.
Study Design and Participants
This was a two-arm, randomized, open-label trial nested within
an active observational cohort study to compare the efficacy and
safety of two versus three-day regimens of dihydroartemisinin-
piperaquine in falciparum and vivax malaria. The study was
conducted in part to identify potential sites to conduct antimalarial
chemoprophylaxis studies. Between September 2010 and March
2011, otherwise healthy civilian and military personnel aged 18 to
65 years were enrolled into the cohort study at two sites in Oddar
Meanchay province near the northern Thai border. Exclusion
criteria included allergic reaction or other contraindication to
dihydroartemisinin or piperaquine, pregnancy, lactation, or
abnormal EKG including a QTc interval greater than 500
milliseconds. Volunteers developing slide-confirmed asexual
falciparum and/or vivax parasites were randomized to receive a
directly observed two or three-day course of dihydroartemisinin-
piperaquine and assessed weekly for malaria for a minimum of 42
days. Volunteers with recurrent malaria received first-line therapy
per national guidelines, which at the time of the study included
artesunate-mefloquine for P. falciparum and chloroquine for P.
vivax. Upon cohort study discharge, volunteers who had developed
vivax infection were treated with commercially-obtained prima-
quine phosphate. Those with normal glucose-6-phosphate dehy-
drogenase (G6PD) activity received 30mg of oral primaquine daily
for 14 days whereas G6PD-deficient volunteers received 45mg of
oral primaquine weekly for eight weeks. To evaluate primaquine
for vivax radical cure and relapse prevention, volunteers had
passive follow-up via monthly clinic visit or telephone interview for
6 months after primaquine administration.
The primary efficacy endpoint was the first occurrence of any-
species treatment failure by 42 days following dihydroartemisinin-
piperaquine administration. Treatment failure was defined as any-
species blood-stage recurrence before Day 42 to include mixed
infection [11]. Secondary endpoints included species-specific
treatment failure, piperaquine pharmacokinetics, drug resistance
characterization, comparative safety outcomes including QTc
prolongation, and 6-month post-primaquine recurrence rates.
Randomization and Masking
Blocked randomization (computer-generated, fixed block size of
two) assigned consecutive volunteers with positive malaria smear
to receive either a two-day or three-day regimen, with treatment
allocation masked from study staff and volunteers in sealed
envelopes. A block size of 2 was chosen to maximize the
comparability of treatment groups between enrollment sites, since
malaria attack rates were not known a priori, and was variability
was anticipated. Duocotecxin provided by Zhejiang Holley Nanhu
Pharmaceutical Co., Ltd was procured by CNM. The two-day
regimen (180mg dihydroartemisinin and 1440mg piperaquine
given at time of diagnosis and then at 24 hours +/21 hour) and
three-day regimen (120mg dihydroartemisinin and 960mg piper-
aquine at time of diagnosis, at 24 hours and 48 hours +/21 hour)
both passed British Pharmacopeia 2004 content and uniformity
standards conducted by AFRIMS Pharmacology Lab [3].
Procedures
After enrollment, cohort volunteers had a baseline history and
physical examination, 12-lead electrocardiogram (ECG), and
laboratory evaluation [thick and thin smears, complete blood
count (CBC), renal function, liver function, and G6PD deficiency
via fluorescent spot test (SQMMR500, R&D Diagnostic). Volun-
teers had weekly assessment for symptoms of Plasmodium infection,
and if symptom-free, monthly blood smears. Volunteers with
clinical suspicion of malaria at routine follow-up, or at any time
during the study, had blood smears. Two blinded microscopists
examined Giemsa-stained thick and thin smears; a third blinded
microscopist determined the final result for discordant readings.
Parasite densities were calculated as a parasite count per 200
WBCs (thick smear) or per 5000 RBCs (thin smear). A total of 200
oil immersion fields were examined on the thick film before it was
considered negative.
Volunteers with slide-confirmed malaria were admitted to an
inpatient facility. Blood smears were made at 0 (first dose), 4, 8
hours, and then every 8 hours along with vital sign measurements.
All treatment was directly observed and given with biscuits and
lactasoy (320kcal, 17g fat) roughly 30–60 minutes before the first
dose was administered. Patients were released to continued
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outpatient follow-up once afebrile with two consecutive negative
smears and therapy completed. They were assessed weekly for
malaria recurrence until cohort discharge, a minimum of 42 days.
For volunteers developing blood stage vivax infection during the
study, primaquine was administered upon cohort study discharge
and directly observed. Pre- and post-primaquine (on day 3 up to
day 28) hemoglobin levels were assessed for safety in patients with
G6PD deficiency, with primaquine halted if greater than 25%
hemoglobin drop was observed after the first dose at day 3.
Plasma piperaquine level sampling at 0, 4, 24, 48, and 72 hours
after the first dose and weekly until day 42 or day of recurrence
was performed using ultra-high performance liquid chromatogra-
Figure 1. Study Schematic Inset and Trial Profile. *Randomization goal met, 2 withdrew. **Prolonged QTc. ¥PCR-corrected speciation. aNot
included are 2nd recurrences (1 Pf, 1 Pv, 1 mixed). bNot included are 2nd recurrences (2 Pf, 5 Pv) and a 3rd recurrence (1 Pv). #Study discharge varied,
median 115 days follow-up.
doi:10.1371/journal.pone.0093138.g001
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phy with tandem mass spectrometry analysis adapted from
previous methods [5]. Briefly, 2 ml of whole blood was collected
into chilled sodium heparin tubes, immediately centrifuged to
separate plasma, frozen at approximately 220uC or below, and
then transferred to Bangkok for analysis by UPLC/MS/MS using
a Waters Acquity TM Ultra Performance LC coupled with a Xevo
TQ-S (Waters, Milford, MA, USA). Chromatographic separation
was performed on an Acquity UPLCH BEH C18 1.7um, 2.1x50
mm analytical column with the same material used for the guard
column at 40uC. The gradient mobile phase was comprised of 5%
200 mM Ammonium acetate pH 9.8, 28% ACN and 50%
MeOH at a flow rate of 0.6 ml/min, using a sample injection
volume of 2 ml with 5-minute run time. The Xevo TQ-S was
equipped with an electrospray ionization source and operated in
the positive ion mode. Data was acquired and processed using
MassLynx version 4.1. Quantification was carried out using multi
reaction mode (MRM) evaluating the transition of m/z from
535.22 to 261.17 and 288.20 (major) for piperaquine and 541.29
to 262.20 and 294.19 (major) SIL-PIP which was used as an
internal standard. A two-compartment model with 1st order
absorption and elimination was developed using Phoenix Win-
Nonlin version 1.3 (Pharsight, USA) to estimate pharmacokinetic
parameters including the maximum concentration by interpola-
tion (Cmax), time to maximum concentration (Tmax), area under
the curve from time 0 to ‘ (AUC0-‘), a t1/2 (alpha – distribution
half life) and b t1/2 (beta – elimination half life). Additional
calculated parameter estimates included clearance divided by
fraction absorbed from the central compartment (Cl/F), inter-
compartmental clearance (ClD2/F), absorption rate constant (k01),
volume of distribution over fraction absorbed from central
compartment (V1/F), and volume of distribution over fraction
absorbed from the peripheral compartment (V2/F).
Fresh falciparum isolates obtained prior to drug administration
were tested at 0, 4, 24, 48, and 72 hours in histidine-rich protein-2
enzyme-linked immunosorbent assays (HRP-2 ELISA) for suscep-
tibility to common antimalarials [12]. Recurrent cases were
distinguished as recrudescence or reinfection by genotyping for
MSP-1 (merozoite specific protein), MSP-2, and GLURP (gluta-
mate-rich protein) allelic variants [13]. Evaluation of pfmdr1 copy
number, pfmdr1 single nucleotide polymorphisms (N86Y, Y184F,
S1034C, N1042D, D1246Y), pvmdr1 copy number, and pfcrt
haplotyping of amino acid positions 72–76 were performed as
previously described [14–20].
Statistical Analysis
Region-specific preliminary data estimated a monthly incidence
of 5–10% during peak malaria season. For the nested treatment
study, sample size estimates were based on published dihydroarte-
misinin-piperaquine falciparum cure rates of approximately 75%
and 98% for the two and three-day regimens respectively [21]. A
total sample size of 76 was required to detect a 25% difference in
efficacy with nominal 80% power using Fisher’s exact test with
a= 0.05 (two-sided) (PASS, 2005).
Three analysis populations were defined: (1) intention-to treat
(ITT) were all volunteers who received at least one treatment dose
with those missing end-point data treated as failures, (2) per-
protocol (PP) were all volunteers who completed treatment and
who had at least 42 days of follow-up, and (3) modified intent-to-
treat (mITT) was the ITT population; and, for mITT efficacy,
persons withdrawn, lost-to-follow-up, or protocol violations were
considered censored at the last study visit. For primaquine given at
study discharge, ad hoc mITT and ITT analyses were conducted
to estimate 6-month relapse prevention.
Descriptive statistics were used to summarize results. Mean
values were compared using t-tests. Geometric means were
compared using log-transformed values. The Wilcoxon rank sum
test was used for non-parametric comparisons. Fisher’s exact test
was used to compare two independent proportions. Confidence





Male patients 39 (97.5) 38 (95)
Weight (kg) (mean, SD) 57.5 (7.2) 57.6 (7.8)
Age (years) (mean, SD) 35.6 (8.3) 32.0 (8.9)
Military personnel 39 (97.5) 38 (95)
History of malaria in previous year 26 (65) 18 (45)
Temperature .37.5uC 11 (28) 17 (43)
G6PD deficiency by fluorescent spot test 8 (20) 5 (13)
Hematocrit (%) (mean, SD) 39.4 (4.3) 40.2 (5.4)
Species at primary infection*
P. falciparum 6 (15) 10 (25)
Geometric mean parasites/mL (95% CI) 994 (211–4686) 2357 (596–9323)
P vivax 33 (80) 28 (70)
Geometric mean parasites/mL (95% CI) 499 (224–1112) 390 (177–858)
Mixed infections 1 (3) 2 (5)
Geometric mean parasites/mL (95% CI) 6130** 3284 (1197–9011)
Presence of vivax gametocytes 21 (53) 18 (45)
Presence of falciparum gametocytes 1 (3) 5 (13)
All data are number (%) unless otherwise indicated. There were no statistical or clinically significant differences between groups. *Non-PCR adjusted. **Only 1 sample in
this subgroup so actual parasitemia reported.
doi:10.1371/journal.pone.0093138.t001
Dihydroartemisinin-Piperaquine Cambodian Military
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e93138
intervals (95%) were computed for all estimates of treatment effect
measures with two-sided P-values reported.
The mITT population was used for primary efficacy analysis
(all-species recurrence by Day 42) and for species-specific
recurrence. Day 42 recurrence rates (95% CI) were estimated
using the Kaplan-Meier method. Cumulative risk curves were
compared using the Cox-Mantel (log-rank) test. Falciparum-specific
analysis was PCR-adjusted to regard true falciparum recrudescence
(alone or mixed infection in both initial and recurrent parasitemia)
as failures and censored new falciparum or vivax infections as non-
failures [22]. Dihydroartemisinin-piperaquine efficacy was also
assessed in both the PP and ITT populations as the proportion of
volunteers with PCR-corrected adequate clinical and parasitolog-
ical response (ACPR) at Day 42. The ITT analysis treated those
with missing endpoint data as failures.
Adverse events (AEs) were monitored from the time of
antimalarial administration until study discharge and assessed for
causality [23]. Given many symptoms attributable to acute
malaria, we compared only symptoms that developed after
dihydroartemisinin-piperaquine administration in the ITT popu-
lation. A 12-lead ECG was performed at the time of infection and
at 24 hour-intervals until treatment completion. QT intervals were
manually measured and corrected using Bazett’s (QTcB = QT/
!RR) and Fridericia’s (QTcF = QT/3!RR) formulae. If electronic
QTcB reading was prolonged $500ms after dosing, study drug
was halted, and an alternative agent was used for treatment. All
statistical analyses were done using SASH software, version 9.3
(SAS Corporation, Carey, NC).




(n = 40) P-value
Therapeutic responses
72-hour positivity, (pos/n)
P. vivax 0/32 0/28 ,
P. falciparum+mixed 4/8 5/12 0.72
[50 (22–78)] [42 (19–68)]
Parasite clearance time, h, median (IQR) 8 (8,24) 16 (8,40) 0.40*
P. vivax 8 (8, 16) 8 (6, 16) 0.96
P. falciparum+mixed 80 (48,88) 68 (44, 104) 0.96
Fever clearance time, h, median (IQR) 16 (10,17) 16 (8, 24) 0.88
Gametocyte clearance time, h, median (IQR) 16 (12,24) 20 (8,40) 0.86
Efficacy outcomes
Early treatment failure, n 0 0
Late treatment failure, n 4 3
ACPR, PCR-adjusted, Day 42
Per-protocol, all-species* 34/38 36/39 0.71
[89 (75–97)] [92 (79–98)]
P. vivax¥ 29/30 27/28 0.74
[97 (83–99)] [96 (82–100)]
P. falciparumJ 6/8 9/11 0.73
[75 (35–97)] [82 (48–98)]
ITT, all-species** 34/40 36/40 0.74
[85 (70–94)] [90 (76–97)]
P. vivax¥ 29/32 27/28 0.62
[91 (75–98)] [96 (82–100)]
P. falciparumJ 6/8 9/12 1.00
[75 (35–99)] [75 (43–95)]
Malaria-free at study discharge***
Per-protocol, all-species 21/38 19/37 0.82
[55 (38–71)] [51 (34–68)]
ITT, all-species 21/40 19/40 0.82
[53 (36–69)] [48 (32–64)]
All data are number [%(95% CI)] unless otherwise indicated; CIs are based on binomial (exact) calculations; p-values are for Fisher’s exact test. *Wilcoxon test was used
for comparing parasite and fever clearance times. ¥Vivax recurrence in those with initial vivax infection. JFalciparum recurrences in volunteers with initial falciparum or
mixed infections (n = 2 in each arm) were all true recrudescences by PCR. One subject with initial falciparum infection developed vivax infection at Day 42 and was
counted as failure in the all-species analysis only. *PP analysis excludes subjects withdrawn or lost-to-follow-up. **ITT analysis treats subjects withdrawn or lost-to-
follow-up as treatment failures. ***Mean (median) follow-up duration 102 days (115 days).
doi:10.1371/journal.pone.0093138.t002
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Results
Between September and December 2010, 256 asymptomatic
volunteers screened for the cohort study, 222 enrolled, and 20%
(51/256) were malaria-infected at baseline (39 vivax, 11 falciparum,
1 mixed) of whom 41 enrolled. Of the 91 developing uncompli-
cated malaria (Figure 1), the first 80 were randomized to
dihydroartemisinin-piperaquine in a nested treatment study
(Table 1). Of the 80, 75% had vivax, 19% had falciparum, and
6% had both species, with three lost to follow-up and one
withdrawal. Gametocytemia was present at diagnosis in 56% (45/
80) overall, and in 65% (39/60) of those with initial vivax infection.
Parasite and gametocyte clearance times were similar in each
group (Table 2). Among 20 volunteers with falciparum, 75% were
parasitemic at 48 hours and 45% at 72 hours. Median falciparum
clearance time was 80 hours (IQR, 48, 88) in the two-day group
and 68 hours (IQR, 44,104) in the three-day group (P = 0.84),
while median asexual vivax parasitemia clearance was 8 hours in
both groups.
There were no early treatment failures (ETF). One volunteer
with vivax infection had therapy switched after a QTc interval
increase .100 milliseconds following the first dose of dihydroar-
temisinin-piperaquine and was censored as a treatment failure.
There were seven late treatment failures (LTF) with the earliest (P.
vivax) occurring at Day 14 in the two-day group. Plasma
piperaquine concentration-time profiles were similar for LTFs
and ACPR (Figure 2A). Geometric mean log AUC0-‘ where it
could be calculated was not significantly lower in late treatment
failures than ACPR using an unpaired T-test (Figure 2B).
All-species efficacy by mITT analysis at Day 42, the primary
endpoint, was 90% (95% CI, 7–19) for two-day and 92.5% (95%
CI, 0–16) for three-day regimens (P = 0.63) (Figure 3A). All species
intention-to-treat efficacy by day 42 was 85% (95% CI 70–94) in
the two-day group versus 90% (95% CI 76–97) in the three-day
group P = 0?74) (Table 2), with vivax-specific ITT efficacy 91%
(95% CI 75–98) and 96% (95% CI 82–100) respectively (P = 0.62)
(Table 2). Incidence of PCR-corrected falciparum recrudescence by
Day 42 was 25% (95% CI, 0–55) and 17% (95% CI, 0–38) for two
and three-day regimens respectively (P = 0.72), but 38% (95% CI
4–71) and 33% (95% CI 7–60) respectively by study discharge
(P = 0.91) (Figure 3B), with ITT efficacy at Day 42 only 75% in
both groups (95% CI 35–99 two-day versus 43–95 three-day)
(Table 2). For those with initial vivax parasitemia, cumulative
incidence of recurrence was 3% in each group at Day 42 (two-day
95% CI, 0–9; three-day 95% CI, 0–10) (Figure 3C). Regimens
were comparable in the proportion remaining vivax malaria-free at
study discharge with 42.5% for two-day (95% CI, 27–58) versus
45% for three-days (95% CI, 30–60) (P = 0.84).
While largely indistinguishable, pharmacokinetic parameters for
piperaquine calculated using a slow and fast clearing 2-compart-
ment model revealed significantly higher Cmax, AUC0-‘ and k01
with the 2 day course but lower terminal elimination half-life (b t1/
2) compared to the 3 day course (Table 3). Ex vivo drug
susceptibility was assessed in 12/16 (75%) isolates from falciparum
cases at Day 0 and compared to 50% inhibitory concentration
(IC50) values at recurrence (Figure S4). Average IC50s at day 0
were higher in recrudescent than non-recrudescent cases, though
the limited number of paired samples prevented assessment of
statistical significance. In all evaluable cases of falciparum recru-
descence, plasma piperaquine levels on day of recurrence were
below Day 0 IC50 whereas levels in all ACPR cases were above
Day 0 IC50 (Figure 4).
Though multiple pfmdr1 copy number at baseline (.1.5) was
more common in recrudescent (3/7), than non-recrudescent cases
(0/13), there was no difference in median Day 0 pfmdr1 copy
number between the 7 recrudescent and 13 non-recrudescent
falciparum cases [1.22 (IQR 1.00, 1.16) versus 1.12 (IQR 1.14,1.61);
p = 0.104]. Copy number increased relative to Day 0 in all three
cases of secondary recurrence (Figure S1). All falciparum isolates
except one contained the184Fpfmdr1 mutation, but wild-type at
codons 86N, 1034S, 1042N, 1246D, and all had the pfcrt CVIET
mutant haplotype associated with chloroquine resistance. In-
creased pvmdr1copy number in vivax isolates was uncommon (7%
of all isolates) and did not increase significantly with recurrent
parasitemia (Table S1) [20].
The most commonly reported adverse events were upper
respiratory infection, headache, and musculoskeletal pain. Only
10% of volunteers developed new complaints not present at
baseline following dihydroartemisinin-piperaquine treatment (Fig-
ure S2). The only serious adverse event (SAE) reported was an
unrelated hospitalization for motorcycle accident six weeks after
dihydroartemisinin-piperaquine administration. There was a
mean QT prolongation of 20–30ms (Figure 5) between pre-dose
and trough drug piperaquine levels, and roughly 18.5% of the 80
subjects dosed had a grade 1 cardiac adverse event due to QT
prolongation during the 3 day period following dosing (Table 4).
Figure 2. Comparison of plasma piperaquine levels between
ACPR and recrudescent patients. (A) Concentration–time profiles
(geometric mean concentrations with 95% CI) for ACPR and recrudes-
cent groups. There were no statistically significant differences beween
groups at any timepoint. (B) AUC0-‘ (2 compartment analysis) in ACPR
and LTF groups. Black lines represent geomean with 95%CI. Note that
AUC could not be calculated in 4 and 2 patients in the ACPR and LTF
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Figure 3. Cumulative incidence of recurrence by modified intention-to-treat analysis at Day 42 and study discharge. (A) No statistical
difference between regimens for all-species recurrence at primary endpoint Day 42 (p = 0.63) and at day of discharge (p = 0.84). (B) In persons with an
initial falciparum parasitemia (alone or mixed), there was no difference in true falciparum recrudescence at Day 42 (p = 0.73) and at day of study
discharge (p = 0.91). (C) In persons with an initial vivax parasitemia (alone or mixed), there was no difference in vivax recurrence at Day 42 (0.94) and
at day of study discharge (p = 0.22).
doi:10.1371/journal.pone.0093138.g003
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There were no significant differences in adverse cardiac events
between the regimens on any of the days measured (Table 4).
At cohort study discharge, 72 volunteers developing vivax
infection received directly observed primaquine treatment. Thir-
teen volunteers were qualitatively G6PD-deficient and received a
weekly 45mg primaquine dose for eight weeks. Prior to starting
primaquine, the mean (SD) baseline hematocrit for the G6PD-
deficient group was 41.2 (3.7) mg/dL (95% CI, 39.0–43.4), similar
to the mean follow-up hematocrit within 1 month of initiating
therapy [40.4 (4.9) mg/dL (95% CI, 38.5–42.3; P = 0.60)]. Only
two G6PD-deficient volunteers had.10% reduction from baseline
hematocrit, dropping 18% and 14% below baseline at 19 and nine
days, respectively, and both resolved within one month with iron
and multivitamin supplementation. Six months of passive follow-
up was completed in person or by phone for 96% (69/72) of
volunteers, the majority of whom remained in the transmission
area. Twenty-six volunteers had recurrences (25 vivax, 4 falciparum)
with no difference between standard and weekly primaquine
regimens (p = 0.19) (Figure S3), with a six-month ITT efficacy for
vivax recurrence of 61% (44/72; 95% CI, 50–72) (Figure 6).
Discussion
In an open-label, randomized trial of two and three-day
dihydroartemisinin-piperaquine regimens, we could not distin-
guish a difference in efficacy for treatment of all-species malaria.
We did find that 42-day treatment failure rates (7.5% and 10%
respectively) were higher than previously reported; however, the
small numbers of treatment failures limits the ability to draw
conclusions on emerging falciparum resistance patterns. The
majority of published studies demonstrated dihydroartemisinin-
piperaquine treatment failure rates of 0–5% in both Africa and
Southeast Asia [6–8]. This is particularly concerning for a
combined malaria endpoint, selected to provide a ‘real world’
assessment of efficacy prior to introduction as first-line therapy for
all malaria in Cambodia, given the poor falciparum efficacy seen (as
low as 75% at Day 42). Prolonged parasite clearance times with
45% Day 3 positivity were observed despite relatively low initial
parasitemia and DOT. Dihydroartemisinin-piperaquine was
efficacious against blood-stage vivax with treatment failure as low
as 3% at Day 42. A recent report indicated falciparum treatment
failure rates as high as 25% in western Cambodia, worsening over
three years (2008–2010), but 100% efficacy in Preah Vihear
province [9]. Despite small numbers of falciparum malaria here, our
findings suggest that the decline in efficacy of dihydroartemisinin-
piperaquine may have already spread to northern Cambodia as
early as 2010.
More importantly, treatment failures had Day 0 parasite ex vivo
IC50 levels in excess of plasma piperaquine levels at the time of
recrudescence, providing evidence for clinical piperaquine resis-
tance. This is concerning given dihydroartemisinin-piperaquine
had been regularly used in this population for only three years
prior. Possible reasons for the rapid decline in dihydroartemisinin-
piperaquine efficacy include private sector availability, self-
treatment, poor compliance, and the long terminal half-life of
piperaquine potentially exposing surviving parasites to subthera-
peutic drug levels [5,24]. In theory, the latter could create a higher
risk of resistance due to the shorter terminal elimination half-life
seen with the 2 day course, but there was otherwise little
pharmacokinetic explanation to favor greater efficacy or risk for
resistance for the 2 or 3 day regimen. Piperaquine pharmacoki-
netic parameters were similar to those reported recently in
Southeast Asian adults, with a long terminal elimination half-life
and similar Cmax for the 3-day course in the fed state, and a higher
Cmax as expected for the 2-day course. While calculated AUC was
larger for the 2-day course, the AUC in the 3-day course was likely
underestimated due to the limited time points available. Short
courses of artemisinins alone as part of an ACT regimen are not
intended by themselves to be curative, but to rapidly clear initial
parasite burden and shorten the febrile period. Because clear
pharmacokinetic-pharmacodynamic relationships have not been
established for either P. falciparum or P. vivax, the relative
contributions of artemisinin levels to therapeutic outcome of
ACTs have yet to be established, and were not measured [25].
Limited sample size, particularly for falciparum, permits neither
definitive conclusions regarding dihydroartemisinin-piperaquine
efficacy nor detailed associations between molecular markers of
drug resistance and treatment failures. However, the high
proportion of falciparum failures, and association with drug levels
Table 3. Pharmacokinetic parameters calculated from a 2-compartment model comparing two versus three-day courses of DHA-
piperaquine.
Pharmacokinetic parameter All Subjects Treatment Group
2 day course 3 day course P-Value*
N 63** 30** 33**
Cmax 1
st dose (ng/ml) 287 (188–282) 391 (228–699) 245 (153–313) 0.003
Tmax 1
st dose (hr) 3.87 (3.44–4.51) 3.69 (3.23–4.42) 3.94 (3.67–4.73) 0.084
AUC0-‘ (hr ? mg/ml) 23.3 (17.7–33.8) 29.1 (20.9–36.6) 19.8 (17.4–26.1) 0.004
a t1/2 (hr) 13.9 (10.4–25.3) 13.9 (10.2–25.6) 14.2 (10.6–25.2) 0.896
b t1/2 (days) 24.7 (18.2–33.3) 21.0 (16.0–28.1) 27.8 (19.7–34.1) 0.029
Cl/F (L/hr) 25.9 (20.2–33.0) 26.5 (21.1–36.9) 25.9 (19.7–29.7) 0.390
ClD2/F (L/hr) 44.3 (30.0–69.6) 39.5 (25.4–55.6) 53.7 (31.7–77.6) 0.077
K01 (L/hr) 0.802 (0.677–0.932) 0.850 (0.748–0.975) 0.767 (0.628–0.900) 0.047
V1/F (L) 1734 (957–2958) 1639 (916–2915) 1778 (1243–2991) 0.549
V2/F (L) 13008 (9302–19519) 12159 (8773–17155) 15555 (9733–19856) 0.106
*Mann-Whitney U test comparing 2 and 3 day treatment groups. **PK analysis could not be performed in 10 and 7 subjects from Group 1 and 2, respectively due to
insufficient time points. PK Parameters are expressed as medians and (25–75% percentiles), with significantly different values in bold.
doi:10.1371/journal.pone.0093138.t003
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Figure 4. Piperaquine plasma concentration-time profiles in relation to IC50 for cases of P. falciparum recrudescence. The pink line
represents the plasma piperaquine concentration, and the green line represents Day 0 IC50, with time of recurrence noted by arrows. Plasma
piperaquine is shown as piperaquine phosphate salt concentration (MW 999?56) to match IC50 calculation method. NI = new infection in case 091. The
IC50 for 149RC could not be assessed due to non-recovery of parasites from the clinical sample.
doi:10.1371/journal.pone.0093138.g004
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below parasite piperaquine IC50s is concerning. Increased Pfmdr1
copy number was not associated with first recurrence, supporting
prior correlations between in vitro piperaquine and chloroquine
sensitivity and Pfmdr1 copy number amplification in Thai-Burmese
falciparum isolates [26]. Nearly all isolates had the Pfmdr1 184F
mutation, associated with mefloquine selective pressure in western
Cambodia [27], and all isolates had mutant pfcrt CVIET haplotype
associated with reduced susceptibility to chloroquine and piper-
aquine [28,29]. Lack of pvmdr1 amplification in vivax infections,
previously associated with decreased chloroquine susceptibility,
also suggests possible chloroquine resistance [30].
While piperaquine was relatively well tolerated with few
treatment-emergent adverse events beyond those associated with
malaria itself, there was a safety signal suggested by the degree of
QT interval prolongation. This signal may have been underesti-
mated as EKGs in our study were obtained at 24-hour trough but
not peak piperaquine concentrations, which typically occur at 4–6
hours post-dose. A food effect cannot be ruled out as a
contributing factor, given that DHA-piperaquine was adminis-
tered with a low-fat (17g) snack. While substantial cardiac safety
signals from DHA-piperaquine were not reported in a prior
regulated multi-center clinical trial [6], and there have been no
case reports of piperaquine-induced Torsades-de-Pointes, nearly
20% of the 80 subjects dosed had at least a grade 1 adverse event
from QT prolongation. Piperaquine has been used in millions of
people without reports of life-threatening cardiotoxicity to our
knowledge. Prior studies have suggested that it may be difficult to
distinguish true drug-induced QT prolongation from the effects of
the underlying illness, fever and tachycardia [31] [32]. However
the mean prolongations seen here of 20–30 milliseconds over
baseline at trough rather than peak post-dose levels were
considerably higher than those previously reported, and warrant
further investigation. We are currently conducting further detailed
investigations regarding this finding (ClinicalTrials.gov -
NCT01624337; NCT01849640).
This is the first study to be carried out in a predominantly
military population in Cambodia since 1977 [7,10,33]. Residing
along endemic borders, often in difficult terrain, mobile popula-
tions represent a critically important group for malaria contain-
ment and elimination efforts. A recent survey of the malaria
elimination program in Sri Lanka highlighted the need to target
mobile gem miners and military personnel [34]. Similarly in
Figure 5. Mean trough QTcF intervals for patients treated daily
with DHA-piperaquine (360/2880 mg cumulative) divided over
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Cambodia, where Plasmodium transmission is geographically
variable, military personnel may act as a reservoir for malaria
transmission to the general population [7,10,33]. The high
proportion of asymptomatic infections at enrollment and low
rates of malaria-free survival over the four months of the cohort
study may pose greater challenges for malaria elimination efforts
than the evidence for piperaquine resistance. The study highlights
limitations of an approach to malaria containment limited to blood
stage agents. There is an unmet need in this setting for both
transmission-blocking and radical treatment of vivax malaria with
primaquine, without which the elimination of vivax may be
impossible. A key positive finding was that primaquine adminis-
tered at cohort discharge was safe and well-tolerated even in
G6PD deficient individuals, despite a 39% vivax six-month
recurrence rate. Despite this, the very small number of G6PD-
deficient patients treated with primaquine, and diagnostics limited
to qualitative fluorescent spot testing does not warrant widespread
use of primaquine without testing in this population. Further
investigations into primaquine safety in G6PD-deficient individ-
uals are currently underway.
Evidence of reduced dihydroartemisinin-piperaquine efficacy
shortly after introduction in Cambodia along with clinical
evidence for piperaquine resistance are concerning. Frequent
recurrences following effective therapy and a potentially large
asymptomatic carrier pool will pose substantial challenges to the
possibility of malaria elimination in Cambodia. Novel antimalarial
development and improved elimination strategies are urgently
needed. In the interim, improvements in case management and
patient follow-up offer the best hope for containing drug-resistant
malaria.
Supporting Information
Figure S1 Pfmdr1 copy number from baseline infection,
1st recurrence and 2nd recurrence. Pfmdr1 copy number for
initial falciparum cases (n = 20 along x-axis) at baseline infection
(blue), 1st recurrence (red) and 2nd recurrence (green).
(TIF)
Figure S2 Symptoms on Day 1 or 2 not reported at
baseline according to treatment arm. Symptoms reported
on Day 1 or 2 in patients without symptoms on admission
according to treatment arm (top bar, red, 3-day DP regimen;
bottom bar, blue, 2-day DP regimen).
(TIF)
Figure S3 Reported malaria episodes after administra-
tion of primaquine in G6PD-deficient versus G6PD-
normal individuals. Over 6-month follow-up in person or by
telephone, there was no difference in malaria recurrence between
G6PD-deficient (n = 6) and G6PD-normal volunteers (n = 20)
(p = 0?19). One vivax recurrence in Month 4 occurred in the
same individual who relapsed in Month 1. During Months 5 and
6, there were 3 volunteers with previous vivax recurrences who
also had falciparum episodes, and 1 volunteer had falciparum
infection in Month 6 with no vivax recurrence after primaquine
administration.
(TIF)
Figure S4 Ex vivo drug susceptibility at day 0 and day of
recurrence for falciparum infection. Black symbols repre-
sent IC50 of parasites from ACPR patients with mean values
Figure 6. Six-month cumulative incidence of reported vivax recurrence following primaquine administration. Cumulative incidence
(Kaplan-Meier) of reported vivax recurrence in 2-day (n = 37) versus 3-day (n = 29) regimens following primaquine (PQ) administration at study
discharge by monthly follow-up in 66 volunteers over 6 months (P = 0.62). Six cohort volunteers who were not randomized to dihydroartemisinin-
piperaquine treatment also developed vivax infection and received primaquine, but are not included in analysis above. *G6PD-normal volunteers
received daily primaquine30mg for 14 days whereas G6PD-deficient volunteers received a weekly regimen of 45mg for 8 weeks.
doi:10.1371/journal.pone.0093138.g006
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displayed below in black, while blue symbols/text represent IC50
and mean IC50 at baseline respectively of parasites from
recurrences. Mean differences in IC50 between paired samples
are displayed as ‘‘D= ’’.
(TIF)
Table S1 Pvmdr1 copy number in initial and recurrent
vivax parasitemia.
(DOCX)
Checklist S1 CONSORT Checklist.
(DOC)
Protocol S1 Trial Protocol.
(PDF)
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